ID   WSU-FSCCL
AC   CVCL_1903
SY   WSUFSCCL
DR   EFO; EFO_0006776
DR   ArrayExpress; E-MTAB-2706
DR   BioSample; SAMN03472504
DR   DepMap; ACH-001708
DR   DSMZ; ACC-612
DR   DSMZCellDive; ACC-612
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001002554
DR   GEO; GSM1308987
DR   GEO; GSM1308988
DR   GEO; GSM1308989
DR   GEO; GSM1308990
DR   PharmacoDB; WSUFSCCL_1676_2019
DR   Wikidata; Q54994468
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=8221615;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=26589293;
RX   PubMed=28196595;
WW   https://bioivt.com/wsu-heme-onc-cell-lines
WW   https://tcpaportal.org/mclp/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: MD Anderson Cell Lines Project.
CC   Doubling time: ~26 hours (PubMed=8221615); ~20-30 hours (DSMZ=ACC-612).
CC   HLA typing: A*02:01,02:01; B*27:05,44:02; C*01:02,05:01; DQA1*02:01,03:02; DQB1*03:02,03:02; DRB1*04:04,07:01 (PubMed=26589293).
CC   Omics: Deep exome analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
ST   Source(s): DSMZ; PubMed=25877200
ST   Amelogenin: X,Y
ST   CSF1PO: 12
ST   D13S317: 11,13
ST   D16S539: 11,13
ST   D18S51: 13,14
ST   D19S433: 14
ST   D21S11: 30
ST   D2S1338: 23,24
ST   D3S1358: 15,16
ST   D5S818: 12
ST   D7S820: 10,13
ST   D8S1179: 12,14
ST   FGA: 22,24
ST   Penta D: 9,13
ST   Penta E: 7,12
ST   TH01: 9.3
ST   TPOX: 11
ST   vWA: 18,20
DI   NCIt; C3465; Grade 1 follicular lymphoma
DI   ORDO; Orphanet_545; Follicular lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   37Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 28
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=8221615; DOI=10.1016/0165-4608(93)90132-6;
RA   Mohammad R.M., Mohamed A.N., Smith M.R., Jawadi N.S., Al-Katib A.;
RT   "A unique EBV-negative low-grade lymphoma line (WSU-FSCCL) exhibiting
RT   both t(14;18) and t(8;11).";
RL   Cancer Genet. Cytogenet. 70:62-67(1993).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//